ACS Chemical Biology · 2017 · 29 citations · 15 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryMolecular PharmacologyDrug-receptor InteractionsEnzyme InhibitionFragment-based Drug DesignFragment-based Lead DiscoveryLigand BindingLigand-based DesignEx Vivo ModelsFragment-based DiscoveryFragment-based Ligand DesignMinimal Effective ConcentrationMycobacterium Tuberculosis InfectionNovel Antibacterial Drug DiscoverySecond-line Antituberculosis TherapyTuberculosis Drug Development
Small-molecule inhibitors of the mycobacterial transcriptional repressor EthR have previously been shown to act as boosters of the second-line antituberculosis drug ethionamide. Fragment-based drug discovery approaches have been used in the past to make highly potent EthR inhibitors with ethionamide boosting activity both in vitro and ex vivo. Herein, we report the development of fragment-sized EthR ligands with nanomolar minimum effective concentration values for boosting the ethionamide activity in Mycobacterium tuberculosis whole-cell assays.
15
A Diarylquinoline Drug Active on the ATP Synthase of <i>Mycobacterium tuberculosis</i>
Koen Andries, Peter Verhasselt, Jérôme Guillemont et al. · Science · 2004 · 2.2K citations · Full text
The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis
Ying Zhang, Béate Heym, Douglas B. Young et al. · Nature · 1992 · 1.3K citations · Full text